levoleucovorin and Fasciitis--Necrotizing

levoleucovorin has been researched along with Fasciitis--Necrotizing* in 1 studies

Other Studies

1 other study(ies) available for levoleucovorin and Fasciitis--Necrotizing

Article	Year
Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report. Annals of the Royal College of Surgeons of England, 2017, Volume: 99, Issue:8 Anti-angiogenics have become an important part of the treatment of several types of tumours such as ovarian, breast, lung and colorectal cancer. Necrotising fasciitis has been reported with bevacizumab but no cases have been reported with aflibercept, ramucirumab or regorafenib in patients with colorectal cancer. Necrotising fasciitis is a rare complication affecting one in 5000 bevacizumab users. We report the case of a 64-year-old man with stage IV rectosigmoid cancer under treatment with folinic acid, fluorouracil and irinotecan (FOLFIRI) and aflibercept, who developed a Fournier's gangrene. Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fasciitis, Necrotizing; Fatal Outcome; Fluorouracil; Fournier Gangrene; Humans; Leucovorin; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins	2017

Article

Year

Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report.

Annals of the Royal College of Surgeons of England, 2017, Volume: 99, Issue:8

Anti-angiogenics have become an important part of the treatment of several types of tumours such as ovarian, breast, lung and colorectal cancer. Necrotising fasciitis has been reported with bevacizumab but no cases have been reported with aflibercept, ramucirumab or regorafenib in patients with colorectal cancer. Necrotising fasciitis is a rare complication affecting one in 5000 bevacizumab users. We report the case of a 64-year-old man with stage IV rectosigmoid cancer under treatment with folinic acid, fluorouracil and irinotecan (FOLFIRI) and aflibercept, who developed a Fournier's gangrene.

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fasciitis, Necrotizing; Fatal Outcome; Fluorouracil; Fournier Gangrene; Humans; Leucovorin; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins

2017